The global PD-L1 Biomarker Testing market size was valued at US$ 2897 million in 2024 and is forecast to a readjusted size of USD 26730 million by 2031 with a CAGR of 37.8% during review period.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti鈥揚D-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
This report is a detailed and comprehensive analysis for global PD-L1 Biomarker Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global PD-L1 Biomarker Testing market size and forecasts, in consumption value ($ Million), 2020-2031
Global PD-L1 Biomarker Testing market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global PD-L1 Biomarker Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global PD-L1 Biomarker Testing market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-L1 Biomarker Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-L1 Biomarker Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
PD-L1 Biomarker Testing market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Market segment by Application
Hospital
Diagnostic Center
Others
Market segment by players, this report covers
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe PD-L1 Biomarker Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PD-L1 Biomarker Testing, with revenue, gross margin, and global market share of PD-L1 Biomarker Testing from 2020 to 2025.
Chapter 3, the PD-L1 Biomarker Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and PD-L1 Biomarker Testing market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of PD-L1 Biomarker Testing.
Chapter 13, to describe PD-L1 Biomarker Testing research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of PD-L1 Biomarker Testing by Type
1.3.1 Overview: Global PD-L1 Biomarker Testing Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global PD-L1 Biomarker Testing Consumption Value Market Share by Type in 2024
1.3.3 PD-L1 (22C3)
1.3.4 PD-L1(28-8)
1.3.5 PD-L1 (SP142)
1.3.6 PD-L1 (SP263)
1.3.7 Other
1.4 Global PD-L1 Biomarker Testing Market by Application
1.4.1 Overview: Global PD-L1 Biomarker Testing Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Diagnostic Center
1.4.4 Others
1.5 Global PD-L1 Biomarker Testing Market Size & Forecast
1.6 Global PD-L1 Biomarker Testing Market Size and Forecast by Region
1.6.1 Global PD-L1 Biomarker Testing Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global PD-L1 Biomarker Testing Market Size by Region, (2020-2031)
1.6.3 North America PD-L1 Biomarker Testing Market Size and Prospect (2020-2031)
1.6.4 Europe PD-L1 Biomarker Testing Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific PD-L1 Biomarker Testing Market Size and Prospect (2020-2031)
1.6.6 South America PD-L1 Biomarker Testing Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa PD-L1 Biomarker Testing Market Size and Prospect (2020-2031)
2 Company Profiles
2.1 Agilent Technologies
2.1.1 Agilent Technologies Details
2.1.2 Agilent Technologies Major Business
2.1.3 Agilent Technologies PD-L1 Biomarker Testing Product and Solutions
2.1.4 Agilent Technologies PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Agilent Technologies Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche PD-L1 Biomarker Testing Product and Solutions
2.2.4 Roche PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Roche Recent Developments and Future Plans
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck PD-L1 Biomarker Testing Product and Solutions
2.3.4 Merck PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Merck Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Product and Solutions
2.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca PD-L1 Biomarker Testing Product and Solutions
2.5.4 AstraZeneca PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Ono Pharmaceutical
2.6.1 Ono Pharmaceutical Details
2.6.2 Ono Pharmaceutical Major Business
2.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Product and Solutions
2.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Ono Pharmaceutical Recent Developments and Future Plans
2.7 Regeneron
2.7.1 Regeneron Details
2.7.2 Regeneron Major Business
2.7.3 Regeneron PD-L1 Biomarker Testing Product and Solutions
2.7.4 Regeneron PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Regeneron Recent Developments and Future Plans
2.8 Innovent
2.8.1 Innovent Details
2.8.2 Innovent Major Business
2.8.3 Innovent PD-L1 Biomarker Testing Product and Solutions
2.8.4 Innovent PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Innovent Recent Developments and Future Plans
2.9 Hengrui Medicine
2.9.1 Hengrui Medicine Details
2.9.2 Hengrui Medicine Major Business
2.9.3 Hengrui Medicine PD-L1 Biomarker Testing Product and Solutions
2.9.4 Hengrui Medicine PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Hengrui Medicine Recent Developments and Future Plans
2.10 Junshi Biosciences
2.10.1 Junshi Biosciences Details
2.10.2 Junshi Biosciences Major Business
2.10.3 Junshi Biosciences PD-L1 Biomarker Testing Product and Solutions
2.10.4 Junshi Biosciences PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Junshi Biosciences Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global PD-L1 Biomarker Testing Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of PD-L1 Biomarker Testing by Company Revenue
3.2.2 Top 3 PD-L1 Biomarker Testing Players Market Share in 2024
3.2.3 Top 6 PD-L1 Biomarker Testing Players Market Share in 2024
3.3 PD-L1 Biomarker Testing Market: Overall Company Footprint Analysis
3.3.1 PD-L1 Biomarker Testing Market: Region Footprint
3.3.2 PD-L1 Biomarker Testing Market: Company Product Type Footprint
3.3.3 PD-L1 Biomarker Testing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global PD-L1 Biomarker Testing Consumption Value and Market Share by Type (2020-2025)
4.2 Global PD-L1 Biomarker Testing Market Forecast by Type (2026-2031)
5 Market Size Segment by Application
5.1 Global PD-L1 Biomarker Testing Consumption Value Market Share by Application (2020-2025)
5.2 Global PD-L1 Biomarker Testing Market Forecast by Application (2026-2031)
6 North America
6.1 North America PD-L1 Biomarker Testing Consumption Value by Type (2020-2031)
6.2 North America PD-L1 Biomarker Testing Market Size by Application (2020-2031)
6.3 North America PD-L1 Biomarker Testing Market Size by Country
6.3.1 North America PD-L1 Biomarker Testing Consumption Value by Country (2020-2031)
6.3.2 United States PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
6.3.3 Canada PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
6.3.4 Mexico PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
7 Europe
7.1 Europe PD-L1 Biomarker Testing Consumption Value by Type (2020-2031)
7.2 Europe PD-L1 Biomarker Testing Consumption Value by Application (2020-2031)
7.3 Europe PD-L1 Biomarker Testing Market Size by Country
7.3.1 Europe PD-L1 Biomarker Testing Consumption Value by Country (2020-2031)
7.3.2 Germany PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
7.3.3 France PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
7.3.4 United Kingdom PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
7.3.5 Russia PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
7.3.6 Italy PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Type (2020-2031)
8.2 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Application (2020-2031)
8.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region
8.3.1 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Region (2020-2031)
8.3.2 China PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
8.3.3 Japan PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
8.3.4 South Korea PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
8.3.5 India PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
8.3.7 Australia PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
9 South America
9.1 South America PD-L1 Biomarker Testing Consumption Value by Type (2020-2031)
9.2 South America PD-L1 Biomarker Testing Consumption Value by Application (2020-2031)
9.3 South America PD-L1 Biomarker Testing Market Size by Country
9.3.1 South America PD-L1 Biomarker Testing Consumption Value by Country (2020-2031)
9.3.2 Brazil PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
9.3.3 Argentina PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Type (2020-2031)
10.2 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Application (2020-2031)
10.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country
10.3.1 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Country (2020-2031)
10.3.2 Turkey PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
10.3.4 UAE PD-L1 Biomarker Testing Market Size and Forecast (2020-2031)
11 Market Dynamics
11.1 PD-L1 Biomarker Testing Market Drivers
11.2 PD-L1 Biomarker Testing Market Restraints
11.3 PD-L1 Biomarker Testing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 PD-L1 Biomarker Testing Industry Chain
12.2 PD-L1 Biomarker Testing Upstream Analysis
12.3 PD-L1 Biomarker Testing Midstream Analysis
12.4 PD-L1 Biomarker Testing Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
听
听
*If Applicable.
